688062 迈威生物
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额(33,924)(956,444)(782,728)(719,171)(422,403)
投资活动产生之现金流量净额(100,226)(291,554)(509,623)(602,803)12,836
筹资活动产生之现金流量净额295,364831,698444,9363,715,810198,942
汇率变动对现金及现金等价物的影响(154)2331,4032,264(1,006)
现金及现金等价物净增加/(减少)161,060(416,067)(846,011)2,396,100(211,630)
期初现金及现金等价物余额1,227,5661,643,6332,489,64593,545305,175
期末现金及现金等价物余额1,388,6261,227,5661,643,6332,489,64593,545